Showing results (41-50 of 67) with videos related to

Sort By:
Pageof 7
Molecular Medicine (Cambridge, Mass.)|November 4, 2024
N6-methyladenosine and its epitranscriptomic effects on hematopoietic stem cell regulation and leukemogenesisKao-Jung Chang, Li-Yang Shiau, Shiuan-Chen Lin, et al.
Hematological Oncology|October 28, 2022
Prognostic factors in patients with bone marrow hemophagocytosis and its association with hematologic malignanciesJing-Gu Jiang, Chia-Jen Liu, Chiu-Mei Yeh, et al.
Cancer Medicine|January 17, 2023
Long-term outcomes of frontline intensification in primary CNS lymphoma: A real-world single-center experienceHao-Yuan Wang, Ching-Fen Yang, Chia-Hsin Lin, et al.
Plos One|February 15, 2017
The uniqueness of morphological features of pure erythroid leukemia in myeloid neoplasm with erythroid predominance: A reassessment using criteria revised in the 2016 World Health Organization classificationPo-Shen Ko, Yao-Chung Liu, Chiu-Mei Yeh, et al.
Blood Neoplasia|January 15, 2026
Ratios of CD8 T lymphocytes to M-MDSCs (CD8MMR) predict prognosis in patients with untreated DLBCLHao-Yuan Wang, Fu-Chen Yang, Ching-Fen Yang, et al.
Scientific Reports|August 15, 2019
Risk factors and clinical features for post-transplant thoracic air-leak syndrome in adult patients receiving allogeneic haematopoietic stem cell transplantationYao-Chung Liu, Yi-Hsin Chou, Po-Shen Ko, et al.
Cancer Medicine|September 21, 2022
Herpes zoster prophylaxis: Essential for treating newly diagnosed multiple myeloma patientsWen-Ying Lin, Chun-Kuang Tsai, Chiu-Mei Yeh, et al.
Hematological Oncology|February 4, 2020
The landscape of BCR-ABL mutations in patients with Philadelphia chromosome-positive leukaemias in the era of second-generation tyrosine kinase inhibitorsSheng-Hsuan Chien, Hsueng-Mei Liu, Po-Ming Chen, et al.
Cancer Medicine|January 6, 2020
The risk of early mortality in elderly patients with newly diagnosed acute myeloid leukemiaChia-Jen Liu, Ying-Chung Hong, Ai Seon Kuan, et al.
British Journal of Haematology|March 25, 2017
Carfilzomib induces leukaemia cell apoptosis via inhibiting ELK1/KIAA1524 (Elk-1/CIP2A) and activating PP2A not related to proteasome inhibitionChun-Yu Liu, Feng-Shu Hsieh, Pei-Yi Chu, et al.
Pageof 7